Fifty-year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water. 2007

Guillermo Marshall, and Catterina Ferreccio, and Yan Yuan, and Michael N Bates, and Craig Steinmaus, and Steve Selvin, and Jane Liaw, and Allan H Smith
Departamento de Salud Pública, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

BACKGROUND Region II of Chile (the second most northerly administrative region) experienced dramatic increases in average arsenic water concentrations beginning in 1958, followed by marked declines in the 1970s when water treatment plants were installed. This history provides a unique opportunity to study time trends in the development of arsenic-related cancers, including lung and bladder cancers. METHODS We investigated lung and bladder cancer mortality from 1950 to 2000 for region II compared with region V, where drinking water was not contaminated with arsenic. Mortality data were obtained from 218,174 death certificates for the two regions for 1950-1970 and from mortality data tapes that identified 307,541 deaths in the two regions for 1971-2000. Poisson regression models were used to identify time trends in rate ratios (RRs) of mortality from lung and bladder cancers comparing region II with region V. RESULTS Lung and bladder cancer mortality rate ratios for region II compared with region V started to increase about 10 years after high arsenic exposures commenced and continued to rise until peaking in 1986-1997. The peak lung cancer mortality RRs were 3.61 (95% confidence interval [CI] = 3.13 to 4.16) for men and 3.26 (95% CI = 2.50 to 4.23) for women. The peak bladder cancer RRs were 6.10 (95% CI = 3.97 to 9.39) for men and 13.8 (95% CI = 7.74 to 24.5) for women. Combined lung and bladder cancer mortality rates in region II were highest in the period 1992-1994, with mortality rates of 153 and 50 per 100,000 men and women, respectively, in region II compared with 54 and 19 per 100,000 in region V. CONCLUSIONS Such large increases in total population cancer mortality rates have, to our knowledge, not been documented for any other environmental exposure. The long latency pattern is noteworthy, with mortality from lung and bladder cancers continuing to be high until the late 1990s, even though major decreases in arsenic exposure occurred more than 25 years earlier.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D002677 Chile A country in southern South America, bordering the South Pacific Ocean, between Argentina and Peru.
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old

Related Publications

Guillermo Marshall, and Catterina Ferreccio, and Yan Yuan, and Michael N Bates, and Craig Steinmaus, and Steve Selvin, and Jane Liaw, and Allan H Smith
April 1998, American journal of epidemiology,
Guillermo Marshall, and Catterina Ferreccio, and Yan Yuan, and Michael N Bates, and Craig Steinmaus, and Steve Selvin, and Jane Liaw, and Allan H Smith
January 2000, Cancer investigation,
Guillermo Marshall, and Catterina Ferreccio, and Yan Yuan, and Michael N Bates, and Craig Steinmaus, and Steve Selvin, and Jane Liaw, and Allan H Smith
March 1996, Epidemiology (Cambridge, Mass.),
Guillermo Marshall, and Catterina Ferreccio, and Yan Yuan, and Michael N Bates, and Craig Steinmaus, and Steve Selvin, and Jane Liaw, and Allan H Smith
March 2004, Cancer causes & control : CCC,
Guillermo Marshall, and Catterina Ferreccio, and Yan Yuan, and Michael N Bates, and Craig Steinmaus, and Steve Selvin, and Jane Liaw, and Allan H Smith
March 1995, American journal of epidemiology,
Guillermo Marshall, and Catterina Ferreccio, and Yan Yuan, and Michael N Bates, and Craig Steinmaus, and Steve Selvin, and Jane Liaw, and Allan H Smith
November 1992, British journal of cancer,
Guillermo Marshall, and Catterina Ferreccio, and Yan Yuan, and Michael N Bates, and Craig Steinmaus, and Steve Selvin, and Jane Liaw, and Allan H Smith
August 1998, International journal of epidemiology,
Guillermo Marshall, and Catterina Ferreccio, and Yan Yuan, and Michael N Bates, and Craig Steinmaus, and Steve Selvin, and Jane Liaw, and Allan H Smith
September 2013, American journal of epidemiology,
Guillermo Marshall, and Catterina Ferreccio, and Yan Yuan, and Michael N Bates, and Craig Steinmaus, and Steve Selvin, and Jane Liaw, and Allan H Smith
August 2016, The American journal of nursing,
Guillermo Marshall, and Catterina Ferreccio, and Yan Yuan, and Michael N Bates, and Craig Steinmaus, and Steve Selvin, and Jane Liaw, and Allan H Smith
January 2014, Toxicology and applied pharmacology,
Copied contents to your clipboard!